BDTX (Black Diamond Therapeutics) EBIT per Share: $-0.80 (TTM As of Mar. 2026)


BDTX Black Diamond Therapeutics Inc BDTX
37 GF Score
Price $1.94
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics EBIT per Share?

Black Diamond Therapeutics BDTX -3.48% 37 EBIT per Share is $-0.80 as of Mar. 2026. GuruFocus rates BDTX with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,174 Biotechnology companies, Black Diamond Therapeutics ranks worse than 85178.79% on this metric.

Black Diamond Therapeutics's EBIT per Share for the three months ended in Mar. 2026 was $-0.20. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.80.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Black Diamond Therapeutics's EBIT per Share or its related term are showing as below:

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Black Diamond Therapeutics was 25.80% per year. The lowest was -76.50% per year. And the median was -41.60% per year.

BDTX's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Black Diamond Therapeutics's EBIT for the three months ended in Mar. 2026 was $-11.26 Mil.

Black Diamond Therapeutics  (NAS:BDTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Black Diamond Therapeutics EBIT per Share Related Terms

Black Diamond Therapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics EBIT per Share Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only -3.51 -2.56 -1.97 -1.43 0.35

Black Diamond Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 -0.24 -0.19 -0.18 -0.20
BDTX
37GF Score
Black Diamond Therapeutics Inc BDTX
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Black Diamond Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=19.87/57.563
=0.35

Black Diamond Therapeutics's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-11.259/57.233
=-0.20

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.80 mean?
Black Diamond Therapeutics (BDTX) has a EBIT per Share of $-0.80 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Black Diamond Therapeutics and its competitors. According to the industry distribution chart, Black Diamond Therapeutics ranks #999999 out of 1174 companies in the Biotechnology industry.
Is Black Diamond Therapeutics' EBIT per Share too high?
Black Diamond Therapeutics' current EBIT per Share is $-0.80. Based on the distribution chart, Black Diamond Therapeutics ranks #999999 out of 1174 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Black Diamond Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' EBIT per Share compare to CGTX and PMN?
According to the Biotechnology industry distribution chart, Black Diamond Therapeutics ranks #999999 out of 1174 companies for EBIT per Share. This places Black Diamond Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Black Diamond Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Black Diamond Therapeutics's current EBIT per Share is $-0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current EBIT per Share of $-0.80. The current EBIT per Share is $-0.80. Black Diamond Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current EBIT per Share is $-0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
37GF Score

Get the complete analysis for BDTX

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.94
Price